книги2 / 283

Механизмы прогрессирования хронической болезни почек у детей

212.Peng J, Li X, Zhang D, et al. Hyperglycemia, p53 and mythochondrial pathway of apoptosis are involved in the susceptibility of diabetic models to ischemic acute kindey injury. Kidney Int. 2015;87(1):137–150.

213.Shankland SJ. The podocyte’s response to injury: Role in proteinuria and glomerulosclerosis. Kidney Int. 2006;69(12):2131–2147.

214.Kimura N, Yonemoto S, Machiguchi T, et al. Synthetic/secreting and apoptotic phenotypes in renal biopsy tissues from hypertensive nephrosclerosis patients. Hypertens Res. 2006;29(8):573–580.

215.Perianayagam MC, Murray SL, Balakrishnan VS, et al. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney disease. J Lab Clin Med. 2000;136(4):320–327.

216.Troyanov S, Hébert MJ, Masse M, et al. Soluble Fas: a novel predictor of atherosclerosis in dialysis patients. Am J Kidney Dis. 2003;41(5): 1043–1051.

217.Леонтьева Ю. А., Паунова С. С., Кучеренко А. Г., и др. Концентрация в моче матриксных металлопротеиназ-2 и -9 и их тканевых ингибиторов у детей с пиелонефритом // Клиническая нефрология. 2011; (5):54–57.

218.Coppo R, D’Amico G. Factors predicting progression of IgA nephropathies J Nephrol. 2005;18(5):503–512.

219.Bottinger E. TGF-β in renal injury and disease. Semin Nephrol. 2007; 27(3):309–320.

220.Van Vliet A, Baelde HJ, Vleming LJ, et al. Distribution of fibronectin isoforms in human renal disease. J Pathol. 2001;193(2):256–262.

221.Reilly JT, Nash JR. Fibronectin (serum spreading factor): its localization in normal and fibrotic tissue. J Clin Pathol. 1988;41(12):1269–1272.

222.Brenner ВМ. AMGEN International Prize: the history and future of renoprotection. Kidney Int. 2003;64(4):1163–1168.

223.Jia G, Kwon M, Liang HL, et al. Chronic treatment with lisinopril decreases proliferative and apoptotic pathways in autosomal recessive polycystic kidney disease. Pediatr Nephrol. 2010;25(6):1139–1146.

224.Kida Y, Tchao BN, Yamaguchi I. Peritubular capillary rarefaction: a new therapeutic target in chronic kidney disease. Pediatr Nephrol. 2014; 29(3):333–342.

225.Rubel D, Stock J, Ciner A, Antifibrotic, nephroprotective effects of paricalcitol versus calcitriol on top of ACE-inhibitor therapy in the COL4A3 knockout mouse model for progressive renal fibrosis. Nephrol Dial Transplant. 2014;29(5):1012–1019.

121

Механизмы прогрессирования хронической болезни почек у детей

226.Chesney RW, Brewer E, Moxey-Mims M, et al. Report of an NIH task force on research priorities in chronic kidney disease in children. Pediatr Nephrol. 2006;21(1):14–25.

227.Soares CM, Diniz JS, Lima EM, et al. Clinical outcome of children with chronic kidney disease in a pre-dialysis interdisciplinary program. Pediatr Nephrol. 2008;23(11):2039–2046.

228.Vivian E, Mannebach C. Therapeutic approaches to slowing the progression of diabetic nephropathy — is less best? Drugs Context. 2013; 2013:212249.

229.Furth SL, Pierce C, Hui WF, et al. Estimating Time to ESRD in Children With CKD. Am J Kidney Dis. 2018;71(6):783–792.

122

ФГАУ «НМИЦ ЗДОРОВЬЯ ДЕТЕЙ» МИНЗДРАВА РОССИИ

ИНФОРМАЦИОННЫЕ МАТЕРИАЛЫ

О.В. Комарова, А.Н. Цыгин, А.П. Фисенко

МЕХАНИЗМЫ ПРОГРЕССИРОВАНИЯ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК У ДЕТЕЙ

Выпускающий редактор У.Г. Пугачёва Литературный редактор М.Н. Шошина Верстка Е.А. Трухтанова

Подписано в печать 13.12.2019. Формат 70х100/16. Усл. печ. л. 10,075. Тираж 1000 экз. Заказ 190375.

Отпечатано ООО «Полиграфист и издатель» 119501, г. Москва, ул. Веерная, 22-3-48